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Introduction
Breast cancer remains a socially significant 
problem despite the reduced early mortality from the 
disease in recent years. In a few patients, disease 
progression after 5 years or more of disease-
free survival (DFS) has been observed during 
follow-up [1], [2]. Established behavioral protocols 
and principled treatment settings not only determine 
improvements in treatment outcomes but also have 
the risk of a lack of individual approach in high-risk 
groups where the percentage of patients with a 5-year 
survival rate is unsatisfactory low. An expression of the 
tendency to understand the biology (“individuality”) of 
a tumor with its specificity of progression and “cellular 
communication” is its differentiation into molecular 
subtypes [3], [4], [5]. This has created hope in 
differentiating and optimizing the therapeutic approach 
in high-risk groups. The expected treatment outcome 
improved and allowed for the development of multiple 
strategies for seemingly “one disease” [6], [7], [8]. Thus, 
molecular subtypes in breast cancer determine the 
daily clinical practice [9] proposed in 2011 by the expert 
panel of St. Gallen [10] and approved in 2013 [11], [12].
The purpose of our study was to determine the 
importance of established molecular subtypes in the 
prognosis and the importance of disease-free and overall 
survival (OS) in patients with non-metastatic breast cancer.
Materials and Methods
The study included 94 patients with non-
metastatic breast carcinoma staged and operated at 
the Clinic for Surgical Diseases at University hospital 
“Prof. Dr. Stoyan Kirkovich,” Stara Zagora for the period 
2010–2018. The criteria for inclusion in the group were 
as follows:
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1. Lack of hematogenous metastases in clinical 
staging
2. Т1, Т2 tumors
3. Lack of need for neoadjuvant therapy
4. Invasive cancer
5. Immunohistochemically typed carcinoma and 
defined as Luminal A, Luminal B/HER2 (−), 
Luminal B/HER2 (+), HER2 overexpressing, 
and triple-negative
6. 60-month followed up patients with sufficient 
information on DFS and OS
7. Absence of synchronous tumor of the same 
side – or contralateral breast
8. Up to N2 in pathohistological staging.
All patients with ultrasound and mammography 
data for potentially malignant, solid breast tumor 
underwent clinical staging with:
1. Ultrasound of breast and axilla
2. Mammography
3. CT scan of thorax and abdomen with 
intravenous contrast
4. Serum СА15-3
5. Pelvic X-ray – until 2008.
All patients after staging were discussed by 
a multidisciplinary team, and a primary therapeutic 
approach was defined.
All patients in the study group were treated 
according to a protocol approved in the clinic, based 
on the protocols of St. Galen and the National Cancer 
Center for the country. All analyzed patients underwent 
primary surgery, followed by pathohistological staging and 
typing. In our study group, in 67 (71.3%), we performed 
mastectomy with lymphatic dissection at the I and II levels, 
while the pectoralis minor was preserved and conditions 
for subsequent subpectoral reconstruction were created. 
The pathohistological characteristics of the tumor and 
immunohistological typing are presented in Table 1.
According to the proposed 2011 St. Gallen 
classification, we differentiated the study group into the 
following subtypes (Table 2).
Table 2: Subtypes according to St. Gallen 2011
Subtype ER and PR status HER-2 status Ki-67
Luminal A like (+) pos. (−) neg. <14%
Luminal B/HER2 − like (+) pos. (−) neg. >14%
Luminal B/HER2 + like (+) pos. (+) pos. >14%
HER-2 type (−) neg. (+++) overexpressed NM
Triple-negative (−) neg. (−) neg. NM
All postmenopausal patients in the study group 
and hormone receptor positives received hormone 
therapy as follows: 66.7% – tamoxifen, 15.9% – 
aromatase inhibitors, and 17.4% were without therapy. 
Polychemotherapy received 64.9% of patients according 
to the accepted standard for the country – positive axillary 
LN, high-risk patients (young age, low grade, family, and 
genetic predisposition). Of the chemotherapy recipients, 
14.8% were on CMF (cyclophosphamide, methotrexate, 
and 5 FU) and 85.2% were treated with anthracycline 
based therapy. About 66.7% of patients with HER-2 
overexpressing carcinoma had positive LN, 50.8% of those 
with Luminal A, and about half of the patients with Luminal 
B and triple-negative (50% and 45.5%, respectively).
All patients with organ preserving intervention 
held adjuvant radiotherapy with a total dosage of 50 ± 2 Gy.
In all patients in the study group, we analyzed 
the 5-year OS and DFS and referred it to molecular 
subtypes, lymphatic status, HER-2 status, the presence 
or absence of endocrine therapy for the follow-up 
period, tumor differentiation, and type of surgery.
Statistical analysis
The statistical analyzes were performed using 
SPSS v16.0 (SPSS, Inc.). The Chi-square test and the 
Fisher exact test were used to compare the categorical 
data. The comparison between the independent groups 
was performed with ANOVA, Student’s t-test, Mann–
Whitney U test, and Kruskal–Wallis test depending on the 
normality of distribution. Correlations were tested using 
Spearmen and Person tests. Survival curves were drawn 
using the Kaplan–Meier method, and the difference in 
survival was calculated with the log-rank test. Factors 
with p < 0.05 were considered statistically significant.
Results
The first relapse (distant, locoregional, or 
combined) was the primary starting point for DFS. OS 
Table 1: Pathohistological characteristics
Tumor characteristics n (%)
Histology
Lobular 6 (6.4)
Ductal 82 (87.2)
Other 6 (6.4)
Tumor size (cm)
≤2 46 (48.9)
>2 48 (51.1)
Gradе (G)
1 13 (13.8)
2 68 (72.4)
3 13 (13.8)
pN Stage
N0 47 (50)
N1 30 (31.9)
N2 17 (18.1)
ER
Positive 58 (61.7)
Negative 36 (38.3)
PGR
Positive 61 (64.9)
Negative 33 (35.1)
HER2
Positive 11 (11.7)
Negative 83 (88.3)
Molecular subtypes
Luminal A 59 (62.7)
Luminal B HER 2 (−) neg. 2 (2.1)
Luminal B HER 2 (+) pos. 8 (8.5)
HER 2 overexpressing 3 (3.2)
Triple-negative 22 (23.5)
organ-preserving intervention with lymphatic dissection at 
the levels I and II and analysis of 14 LNs, tumor bed, and 
resection lines. In 27 (28.7%), we performed a modified 
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is calculated from the date of diagnosis to the date of 
death associated with breast cancer. We observed 
the 5-year OS in 92% of patients identified as Luminal 
A; at 50% of Luminal B/HER2 (−) neg.; in 62.5% with 
Luminal B/HER2 (+), in 67% with HER2-overexpressing 
carcinoma; and in 66.7% of patients with triple-negative 
subtype. The total cancer-associated mortality rate in 
the analyzed period reached 15.9% (n = 15).
As starting points in the prognosis of 
progression and survival were as follows:
1. Type of intervention
2. Histological differentiation of the tumor (G)
3. HER-2 status
4. LN status
5. The presence or absence of endocrine therapy 
during the follow-up period
6. Molecular subtypes.
In our study group, in 71.3% of patients, primary 
surgical treatment included organ-preserving operation 
with Grades I and II LN dissection, and modified 
mastectomy was required in 27 patients. In the analysis of 
the type of surgery for DFS and OS, we found that patients 
with organ-preserving operation had a significantly longer 
DFS compared to patients with mastectomy p = 0.019. 
A similar dependence is also found when assigning the 
type of operating procedure to OS p = 0.027 (Figure 1).
Figure 1: Disease-free survival and overall survival by type of surgery
Of course, the type of surgery is not based 
entirely not only on the biology of the tumor but also on 
the concomitant risk factors such as the type of invasive 
carcinoma, breast volume, family burden, and genetic 
typing. One way or another, in the patients at risk, we 
underwent mastectomy, which clearly states that a 
surgical approach served by “maximum radicalism” is 
not determinative of the disease.
Figure 2: Disease-free survival and overall survival associated with 
tumor grade
In our study group, the tumor grading factor 
was associated with longer DFS in patients with well-
differentiated carcinomas, although the dependence 
was not strictly significant p = 0.077. The Kaplan–Meier 
OS curve, according to tumor differentiation (G), 
showed an unfavorable prognosis for patients with low 
differentiation tumors (p = 0.044). Low tumor grade is 
an independent factor associated with earlier tumor 
progression and markedly lower OS (Figure 2).
The preformed Kaplan–Meier assays show 
clearly poorer DFS and OS in HER-2 expressing 
tumors, but due to the likely small number of 
patients, a significant dependence was not achieved 
(p = 0.081; p = 0.055, respectively) (Figure 3).
Figure 3: Disease-free survival and overall survival associated HER-2 
tumor expression
Patients with pathohistologically negative 
axilla showed the highest DFS and OS, while patients 
with metastases in four and more LN had significantly 
worse prognosis (p = 0.000; p = 0.000, respectively) 
(Figure 4).
Figure 4: Disease-free survival and overall survival associated with 
lymphatic status
Cox univariate analysis showed that the 
evaluation of LN is an independent prognostic factor 
for survival, with significantly greater than 4 positive LN 
(pN2) p < 0.001.
Luminal tumors are subject to adjuvant endocrine 
therapy (ER and/or PR positive). Treatment was performed 
with selective estrogen modulators or aromatase inhibitors 
according to menopausal status. Analysis of the association 
between ET and DFS clearly showed that patients with the 
Luminal A subtype had significantly better DFS and OS 
(p = 0.001; p = 0.000, respectively) (Figure 5).
Figure 5: Disease-free survival and overall survival associated with 
endocrine therapy (1 -Luminal A; 2 - Luminal B/HER-2 [−]; 3 - Luminal 
B/HER-2 [+])
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Although the worse curve was observed in 
HER-2 positive patients, the significant association 
was due to the significant difference in prognosis for 
Luminal A tumors.
Based on immunohistochemical typing, we 
differentiated tumors into five molecular subtypes:
1. Luminal A
2. Luminal B/HER-2 (−)
3. Luminal B/HER-2 (+)
4. HER-2 overexpressed
5. Triple-negative.
In constructing, the Kaplan–Meier curves for 
determining the association of molecular type with DFS 
and OS, we found a significantly better prediction in the 
Luminal A group (p = 0.003; p = 0.002, respectively) 
(Figures 6 and 7).
comparison with the other molecular types (p = 0.002; 
p = 0.001, respectively) (Figure 8).
Discussion
Breast cancer is the leading cause of 
death among women worldwide [13], [14]. It is a 
heterogeneous disease associated with clinical, 
pathological, and biological factors that are variable 
from one population to another [15]. They all determine 
tumor aggression, response to therapeutic approach, 
and survival. In this aspect, the introduction of a 
classification aimed at determining the biology of the 
tumor would improve the healing outcomes. Therefore, 
molecular classification of breast cancer is an important 
tool for managing the treatment of these patients. In 
current practice, the definition of molecular subtypes is 
routine and mandatory in daily clinical work. However, 
the real significance of these biological characteristics 
of the tumor remains underestimated until the past few 
years [16], [17], [18].
For years, the prognosis of the disease and 
subsequent “unified” therapy has been conducted 
solely on the basis of the pathohistological staging of 
the disease. High-risk groups have clearly emerged 
over time, showing early progression and short OS 
beyond early age and poor grade [17], [18]. It was this 
that determined the need for understanding the biology 
of the tumor and allowed a better prognosis of the 
disease. In our study group, 72.4% of patients showed 
5-year DFS and nearly 84.1% OS, which defined the low 
stage as an independent prognostic marker. Of course, 
the detailed analysis of the group clearly shows that 
patients with poor differentiation and Luminal B/HER-2 
(+), even in the early phase of the disease, showed 
dramatically lower DFS and OS. On the other hand, 
positive treatment outcomes were also associated with 
a high percentage of the Luminal A subtype in the study 
group. In this study, we focused on a well-defined and 
homogeneous group of patients. The results obtained 
can be expected to be the same in other studies, as is 
evident from the literature to date [19], [20], [8], [21]. 
The results of this study, the accumulated evidence, 
support the prognostic role that tumor biology plays in 
breast cancer.
In our study group, positive axillary LN was a 
significant, independent prognostic marker for shorter 
DFS and OS. Although this is a confirmatory finding, 
we found that patients with up to three positive LN did 
not have significantly worse DFS and OS than patients 
with negative axilla. Therefore, we suggest that single, 
increased LN is likely to be associated with locoregional 
disease.
The dissociation with the literature regarding 
HER-2 expressing tumors is interesting, and the lack 
Figure 6: Disease-free survival and overall survival associated 
with molecular subtypes (1 - Luminal A; 2 - Luminal B/HER-2 (−); 
3 - Luminal B/HER-2 (+); 4 - HER-2 overexpressed; 5 – Triple-negative)
Figure 7: Comparison of disease-free survival and overall survival 
between the Luminal A group and the other four subtypes
The worst prognosis had patients in the Luminal 
B/HER-2 (+) group (p = 0.004; p = 0.003, respectively) 
(Figure 8).
Figure 8: Comparison of disease-free survival and overall survival 
between Luminal B group and the other four subtypes
Overall, Luminal B, regardless of HER-2 
expression, showed a short DFS and OS in direct 
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of significant association with worse DFS and OS. We 
attribute this pattern to the small number of patients in 
the background of a small group who died during the 
follow-up. One way or another, a statistical trend is 
observed, which determines the confirmation of results 
in a larger group.
The surrogate consensus classification of 
breast cancer in St. Gallen 2011 [10] made it possible to 
differentiate risk groups into disease-specific indicators 
– hormonal activity, proliferation, and specific surface 
expression. This aims at defining not only a therapeutic 
approach with better end results but also a differentiated 
prognosis. Defining a high-risk group determines a 
dynamic change in the overall approach to behavior.
In the group analyzed, we clearly emphasize 
and confirm the prognostic significance of molecular 
subtypes in breast cancer patients [20], [8], [21]. We 
were not surprised by the significantly better prognosis in 
patients with Luminal A tumors, apparent dependence, 
and in a number of other studies [22], [18]. In our 
group, Luminal A is the most common subtype (62.7%), 
followed by triple-negative (23.5%), Luminal B/HER2 
(+) (8.5%), and HER2 overexpressing (3.2%). For the 
majority of patients who were Luminal A subtype the 
overall survivall over 5 years is 92%. At the time of more 
effective systemic treatment, HER2 positive tumors 
have an uncertain outcome due to the small number 
of cases. But invariably, in the Luminal B group, we 
surveyed under the auspices of the high proliferative 
index had the shortest DFS and OS. Ki-67 evaluation 
is available in the majority of cases, which allows us 
to differentiate luminary similar HER2 negative tumors. 
Nevertheless, the validity and reliability of Ki-67 are still 
controversial, although it has been widely accepted as 
a cellular marker of proliferation that is widely available 
[23]. The 14% limit for Ki-67 recommended on St. 
Gallen 2011, which was confirmed by Cheang et al. 
[24], is considered critically because of the significant 
variability of results [25], [26], [27]. This dissonance 
is very problematic since the recommendation for or 
against chemotherapy for positive hormonal receptors, 
negative HER2, and G2 tumors depends mainly on 
the Ki-67 threshold. Because of this ambiguity in 
determining the surrogate subtype, it may be difficult 
to compare the end results with other studies using 
different surrogate definitions.
Conclusion
Each molecular subtype has its own specific 
characteristics that can predict DFS and OS, indicating 
that it is important to consider these characteristics when 
choosing a treatment strategy. Thus, in the study of this 
group, patients with Luminal B had a worse prognosis. 
The decision for adjuvant therapy is appropriate to 
be refined by taking into account molecular subtypes, 
which is a prerequisite for individualizing the therapy.
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